bluebird bio
BLUE
BLUE was delisted on the 30th of May, 2025.
104 hedge funds and large institutions have $742M invested in bluebird bio in 2014 Q2 according to their latest regulatory filings, with 41 funds opening new positions, 34 increasing their positions, 21 reducing their positions, and 19 closing their positions.
143% more call options, than puts
Call options by funds: $6.52M | Put options by funds: $2.68M
116% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 19
80% more capital invested
Capital invested by funds: $411M → $742M (+$331M)
62% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 21
25% more funds holding
Funds holding: 83 → 104 (+21)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$16.4M |
| 2 |
Goldman Sachs
New York
|
+$7.85M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$6.84M |
| 4 |
PC
PointState Capital
New York
|
+$6.81M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.43M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
-$25M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$6.62M |
| 3 |
O
OrbiMed
New York
|
-$6.57M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$4.06M |
| 5 |
Millennium Management
New York
|
-$3.73M |
BLUE Hedge Fund Activity: Q2 2014 in Review
104 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in bluebird bio (BLUE) for Q2 2014, worth a combined $742M — up 80% from $411M a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new BLUE positions and 19 closed out — a net gain of 22 holders — while 34 added to existing stakes and 21 trimmed.
The largest buyer was Deerfield Management, adding an estimated $16.4M. The largest seller was Waddell & Reed Financial, exiting entirely with an estimated $25M sold.
- 104 institutional investors held bluebird bio (BLUE) as of Q2 2014, up from 83 in Q1 2014.
- Funds reported $742M of bluebird bio stock for Q2 2014, up 80% quarter-over-quarter.
- 41 funds opened new bluebird bio positions in Q2 2014 and 19 closed out, a net change of +22 holders.
- The largest bluebird bio buyer in Q2 2014 was Deerfield Management, an estimated $16.4M added.
- The largest bluebird bio seller in Q2 2014 was Waddell & Reed Financial, an estimated $25M sold.
Based on aggregated 13F filings for Q2 2014.